0
selected
-
1.
A therapeutic platelet transfusion strategy without routine prophylactic tranfusion is feasible and safe and reduces platelet transfusion numbers significantly: preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation
Wandt H, Wendelin K, Schaefer-Eckart K, Thalheimer M, Schubert MS, Conradi R,, et al.,
Blood. 2008;112((11):): Abstract No. 286.
-
2.
Transfusion of INTERCEPT platelets vs. reference platelets at doses >/=3.0x1011 results in comparable hemostasis and platelet and RBC transfusion requirements. Results of the SPRINT trial
Murphy S, Snyder E, Cable R, Slichter S, Strauss R, McCullough J,, et al.,
Blood. 2003;102((11, Pt 2):):815a.. Abstract No. 3018.
-
3.
Apheresis platelets treated with the INTERCEPT Blood System for pathogen inactivation provide platelet count increments and hemostasis comparable to conventional platelets
Kluter H, Chapuis B, Cazenave J, Hastka J, Beris P, Dufour P,, et al.,
Vox Sanguinis. 2002;83((Suppl 1):):110a.. Abstract No. 331.
-
4.
INTERCEPT platelets are hemostatically as effective as conventional platelets in the prophylaxis and treatment of bleeding: results of the SPRINT trial
Murphy S, Slichter S, McCullough J, Strauss R, Wood L, Lin J,, et al.,
Vox Sanguinis. 2002;83((Suppl 1):):109. Abstract No. 329.
-
5.
Platelets treated with HELINX technology (HPC) are effective for multiple cycles of transfusion support of thrombocytopenia: the euroSPRITE trial
Corash L, Cazenave J, van Rhenen D, Gullikksson H, Pamphilon D, Ljungman P,, et al.,
Transfusion. 2001;41((Suppl):):38S.. Abstract No. S133-040K.
-
6.
Clinical refractoriness and HLA alloimmunisation are infrequent after multiple exposures to INTERCEPT platelets
Sintnicolaas K, van Rhenen D, Cazenave JP, Gulliksson H, Pamphilon D, Ljungman P,, et al.,
Transfusion clinique et biologique. 2001;8((Suppl 1):):133s.. Abstract No. P269.
-
7.
S-59 clearance and kinetics after transfusion of platelets treated with Helinx technology
Corash LM, Paton V, Wages D, Rheinschmidt M, Porter S, Cimino G,, et al.,
Transfusion. 2000;40((Suppl):):37S.. Abstract No. S137-040I.
-
8.
A prospective randomized double-blinded placebo-controlled trial to evaluate the efficacy of acetaminophen and diphenhydramine as premedication for platelet transfusions
Wang SE, Lara P, Lee-Ow A, Reed J, Wang LR, Palmer P,, et al.,
Blood. 2000;96((11):):656a.. Abstract No. 2820.
-
9.
RH-thrombopoietin-derived autologous cryopreserved platelet support for PBPC transplantation
Bentley M, Taylor K, Wright S, Kelly C, Taylor D, Rodwell R,, et al.,
Blood. 2000;96((11):):425a.. Abstract No. 1825.
-
10.
S-59 (Helinx) photochemically treated platelets (plt) are safe and effective for support of thrombocytopenia: results of the Eurosprite phase 3 trial
van Rhenen D, Gulliksson H, Pamphilon D, Cazenave JP, Ljungman P, Davis K,, et al.,
Blood. 2000;96((11):):819a.. Abstract No. 3539.